MINAPHARM Pharmaceuticals Statistics

Total Valuation

MINAPHARM Pharmaceuticals has a market cap or net worth of EGP 1.79 billion. The enterprise value is 4.35 billion.

Market Cap	1.79B
Enterprise Value	4.35B

Important Dates

The next estimated earnings date is Tuesday, April 8, 2025.

Earnings Date	Apr 8, 2025
Ex-Dividend Date	May 8, 2024

Share Statistics

MINAPHARM Pharmaceuticals has 11.06 million shares outstanding. The number of shares has decreased by -0.80% in one year.

Current Share Class	n/a
Shares Outstanding	11.06M
Shares Change (YoY)	-0.80%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	1.66%
Owned by Institutions (%)	n/a
Float	1.10M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.40
PB Ratio	0.41
P/TBV Ratio	0.48
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.98, with an EV/FCF ratio of -6.10.

EV / Earnings	-22.83
EV / Sales	0.98
EV / EBITDA	6.98
EV / EBIT	12.44
EV / FCF	-6.10

Financial Position

The company has a current ratio of 1.16, with a Debt / Equity ratio of 1.27.

Current Ratio	1.16
Quick Ratio	0.77
Debt / Equity	1.27
Debt / EBITDA	9.04
Debt / FCF	-7.91
Interest Coverage	0.69

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Capital (ROIC)	n/a
Revenue Per Employee	9.83M
Profits Per Employee	-422,921
Employee Count	450
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -35.06% in the last 52 weeks. The beta is -0.04, so MINAPHARM Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	-0.04
52-Week Price Change	-35.06%
50-Day Moving Average	178.44
200-Day Moving Average	183.88
Relative Strength Index (RSI)	29.00
Average Volume (20 Days)	1,508

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, MINAPHARM Pharmaceuticals had revenue of EGP 4.42 billion and -190.31 million in losses. Loss per share was -17.20.

Revenue	4.42B
Gross Profit	1.24B
Operating Income	349.38M
Pretax Income	-135.53M
Net Income	-190.31M
EBITDA	571.40M
EBIT	349.38M
Loss Per Share	-17.20

Full Income Statement

Balance Sheet

The company has 3.20 billion in cash and 5.63 billion in debt, giving a net cash position of -2.43 billion or -220.07 per share.

Cash & Cash Equivalents	3.20B
Total Debt	5.63B
Net Cash	-2.43B
Net Cash Per Share	-220.07
Equity (Book Value)	4.45B
Book Value Per Share	390.74
Working Capital	780.88M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 163.28 million and capital expenditures -875.25 million, giving a free cash flow of -711.96 million.

Operating Cash Flow	163.28M
Capital Expenditures	-875.25M
Free Cash Flow	-711.96M
FCF Per Share	-64.35

Full Cash Flow Statement

Margins

Gross margin is 27.95%, with operating and profit margins of 7.90% and -4.16%.

Gross Margin	27.95%
Operating Margin	7.90%
Pretax Margin	-3.06%
Profit Margin	-4.16%
EBITDA Margin	12.92%
EBIT Margin	7.90%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 1.65, which amounts to a dividend yield of 1.02%.

Dividend Per Share	1.65
Dividend Yield	1.02%
Dividend Growth (YoY)	-41.07%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.80%
Shareholder Yield	1.82%
Earnings Yield	-10.65%
FCF Yield	-39.83%

Dividend Details

Stock Splits

The last stock split was on March 19, 2009. It was a forward split with a ratio of 10.

Last Split Date	Mar 19, 2009
Split Type	Forward
Split Ratio	10

Scores

MINAPHARM Pharmaceuticals has an Altman Z-Score of 0.99. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.99
Piotroski F-Score	n/a